Molecular and Cellular Biology, January 2005, p. 525-532, Vol. 25, No. 2
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.2.525-532.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Ottawa Health Research Institute,1 Departments of Cellular and Molecular Medicine and of Medicine, University of Ottawa, Ottawa, Ontario, Canada2
Received 18 August 2004/ Returned for modification 7 September 2004/ Accepted 18 October 2004
Transcriptional coactivator p300 is required for embryonic development and cell proliferation. Valproic acid, a histone deacetylase inhibitor, is widely used in the therapy of epilepsy and bipolar disorder. However, it has intrinsic teratogenic activity through unidentified mechanisms. We report that valproic acid stimulates proteasome-dependent p300 degradation through augmentation of gene expression of the B56
regulatory subunits of protein phosphatase 2A. The B56
3 regulatory and catalytic subunits of protein phosphatase 2A interact with p300. Overexpression of the B56
3 subunit leads to proteasome-mediated p300 degradation and represses p300-dependent transcriptional activation, which requires the B56
3 interaction domain of p300. Conversely, silencing of the B56
subunit expression by RNA interference increases the stability and transcriptional activity of the coactivator. Our study establishes the functional interaction between protein phosphatase 2A and p300 activity and provides direct evidence for signal-dependent control of p300 function.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|